Invivyd (NASDAQ:IVVD) Given Buy Rating at HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 373.93% from the stock’s current price. HC Wainwright also issued estimates for Invivyd’s FY2029 earnings at $0.41 EPS.

A number of other research firms also recently commented on IVVD. Morgan Stanley decreased their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Monday. Finally, EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Invivyd currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Stock Performance

Shares of Invivyd stock opened at $2.11 on Tuesday. The firm has a market cap of $252.40 million, a PE ratio of -1.08 and a beta of 0.61. Invivyd has a 1 year low of $0.35 and a 1 year high of $5.10. The firm’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $0.82.

Insider Activity at Invivyd

In related news, Director Terrance Mcguire sold 160,400 shares of Invivyd stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares in the company, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 816,466 shares of company stock worth $423,214 in the last 90 days. 17.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Invivyd

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new position in shares of Invivyd during the second quarter worth approximately $421,000. Barclays PLC raised its stake in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares during the period. State Street Corp grew its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.